I-Beauty: Why India is the New Trend in Skincare https://ymaho.com/i-beauty-why-india-is-the-new-trend-in-skincare
Learn how Ayurveda and deals by giants like Estée Lauder are making India a leader in the global beauty industry. Detailed analysis of the I-Beauty trend.
Why I procrastinate: the neuroscience of procrastination https://ymaho.com/why-i-procrastinate-the-neuroscience-of-procrastination
Learn how your brain sabotages your plans. A scientific explanation of procrastination and 5 steps to combat it. Start taking action today!
Meme "I Don't Have a Right Hand": story of viral police video https://ymaho.com/meme-i-don-t-have-a-right-hand-story-of-viral-police-video
Video of a police officer who didn't understand a driver without a right hand became a meme. Watch how the phrase "I don't have a right hand" conquered the internet. Read the analysis.
SPAC Aeon Acquisition I IPO at $125M: Acquisition of European Sports https://ymaho.com/spac-aeon-acquisition-i-ipo-at-125m-acquisition-of-european-sports
SPAC Aeon Acquisition I conducted an IPO on Nasdaq at $125M to acquire European basketball. Analysis of the deal, risks, forecasts, and hidden insights for investors. Read more.
FDA approved first gene therapy for LAD-I in children https://ymaho.com/fda-approved-first-gene-therapy-for-lad-i-in-children
FDA approved Kresladi (marnetegragene autotemcel) — the first stem cell gene therapy for children with severe LAD-I. Learn about the mechanism, precedents, and business model. Detailed analysis on the website.
IMP761 — first LAG-3 agonist passes Phase I in autoimmune diseases https://ymaho.com/imp761-first-lag-3-agonist-passes-phase-i-in-autoimmune-diseases
Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.
Marne-Cel FDA approval: gene therapy for LAD-I https://ymaho.com/marne-cel-fda-approval-gene-therapy-for-lad-i
FDA approved Marne-Cel for children with severe LAD-I: 100% survival in trials. Learn how Rocket Pharmaceuticals turned rejections into a breakthrough.
CAR-T therapy for ovarian cancer: lira-cel and 28 months of life https://ymaho.com/car-t-therapy-for-ovarian-cancer-lira-cel-and-28-months-of-life
Updated Phase I data: CAR-T lira-cel showed 28-month survival in ovarian cancer. Learn why this is a breakthrough in solid tumor treatment.
A New Look at Alzheimer's Disease: Roche Tests Spinal ASO Therapy https://ymaho.com/a-new-look-at-alzheimer-s-disease-roche-tests-spinal-aso-therapy
Roche has initiated Phase I trials of intrathecal ASO against ApoE for early Alzheimer's disease. Why this is a revolution, who will benefit, and hidden risks. Read the analysis.
CD4+ T cells kill cancer through ferroptosis: a breakthrough in immunology https://ymaho.com/cd4-t-cells-kill-cancer-through-ferroptosis-a-breakthrough-in-immunology
Scientists have proven: CD4+ T lymphocytes destroy MHC I-negative tumors through ferroptosis. The discovery changes the approach to cancer immunotherapy and treatment of GVHD. Read the details.